It is expected to be available in the second quarter of 2026
Further along, we discuss their FDA approval status and primary functions in managing type 2 diabetes
individuals with a BMI greater than 30 who have heart failure with preserved ejection fraction, uncontrolled hypertension or chronic kidney disease
However, newer GLP-1 medications, such as tirzepatide, which target both GLP-1 and GIP receptors, may be even more effective for weight loss
This combination is not unique to Strive
To overcome the barriers and to improve the adherence, oral GLP-1 RAs were needed, but oral protein-based drug absorption is limited because of degradation in the stomach due to low pH, proteolytic enzyme activity, and limited permeability across the gastrointestinal (GI) epithelium